Clinical TrialJun 2, 2026, 06:12 AM
Lantern Pharma Discusses LP-300 Harmonic™ Phase 2 Clinical Trial
AI Summary
Lantern Pharma Inc. utilized a presentation on June 1, 2026, to facilitate discussions concerning its Harmonic™ Phase 2 clinical trial. The trial involves the company's product candidate, LP-300. The presentation was furnished as Exhibit 99.1 to the Current Report on Form 8-K.
Key Highlights
- Lantern Pharma discussed its Harmonic™ Phase 2 clinical trial.
- The trial is for the company's product candidate, LP-300.
- A presentation was utilized for these discussions on June 1, 2026.
- The presentation is furnished as Exhibit 99.1 to the 8-K filing.
Price Impact
More from LTRN